DDX59-AS1 is a prognostic biomarker and correlated with immune infiltrates in OSCC.
DDX59-AS1 is a prognostic biomarker and correlated with immune infiltrates in OSCC.
复制标题
DDX59-AS1 是一种预后生物标志物，与 OSCC 中的免疫浸润相关
DOI：
10.3389/fgene.2022.892727
复制
发表时间：
2022
影响因子：
3.7
通讯作者：
中科院分区：
文献类型：
--
作者：
背景：LncRNAs在与肿瘤进展相关的基因调控的多个步骤中发挥关键作用。然而，DDX59-AS1作为一种lncRNA的结合仍然不明确，特别是在口腔鳞状细胞癌(OSCC)中。本研究探讨DDX59-AS1在OSSC中的表达及其与免疫浸润的关系，并评价其在OSSC中的预后价值。方法：口腔鳞癌患者来自肿瘤基因组图谱(TCGA)数据库。用Wilcoxon秩和检验比较DDX59-AS1在口腔鳞癌和正常口腔鳞癌组织中的表达。用Logistic回归分析DDX59-AS1与临床病理特征的关系。利用基因本体论(GO)术语分析、基因集浓缩分析(GSEA)和单一样本GSEA(SsGSEA)对DDX59-AS1的浓缩途径和功能进行了解释，并对DDX59-AS1的免疫细胞渗透进行了定量。采用Kaplan-Meier分析和Cox回归分析DDA59-AS1与生存率的相关性。用基于COX多因素分析的诺模图预测DDX59-AS1的预后影响。结果：DDX59-AS1的高表达与T分期、临床分期、种族、年龄显著相关(p<；0.05)。多因素生存分析显示，DDX59-AS1的高表达与较低的总生存率和特定生存率相关。用诺模图和校正曲线对预后预测进行了验证。DDX59-AS1的表达与肥大细胞、Tfh、T细胞、Treg、B细胞呈负相关，与TGD的浸润程度呈正相关。结论：DDX59-AS1在口腔鳞癌的发生发展和预后中起着重要作用，是口腔鳞癌的一个潜在的生物标志物。
Background: lncRNAs play a critical role in multiple steps of gene regulation associated with tumor progression. However, the engagement of DDX59-AS1, a lncRNA, remains equivocal, particularly in oral squamous cell carcinoma (OSCC). In this study, the expression of DDX59-AS1 and its association with immune infiltration were investigated, and its prognostic value in OSSC was evaluated. Methods: OSCC patients were collected from The Cancer Genome Atlas (TCGA) database. The expression of DDX59-AS1 in OSCC and healthy tissue was compared using Wilcoxon rank sum test. The relationship between DDX59-AS1 and clinicopathological features was analyzed using Logistic regression. Gene ontology (GO) terminology analysis, gene set enrichment analysis (GSEA), and single sample GSEA (ssGSEA) were utilized to interpret the enrichment pathway and functionality and to quantify the immune cell infiltration of DDX59-AS1. The correlation between survival and DDA59-AS1 was evaluated by Kaplan-Meier analysis and Cox regression. The prognostic impact of DDX59-AS1 was predicted by the nomogram based on Cox multivariate analysis. Results: High expression of DDX59-AS1 was significantly correlated with T stage, clinical stage, race, and age (p < 0.05). Multivariate survival analysis demonstrated that the high expression of DDX59-AS1 was associated with lower overall and specific survival rates. The prognosis prediction was validated by the nomogram and calibration curves. The expression of DDX59-AS1 was negatively correlated with Mast cells, Tfh, T cells, Treg, and B cells, and positively related with the Tgd infiltration level. Conclusion: DDX59-AS1 played a crucial role in the progression and prognosis of OSCC and was potentially a predictive biomarker for OSCC.